Dhaka trial recommends Favipiravir in COVID-19 treatment | The Daily Star
12:00 AM, July 12, 2020 / LAST MODIFIED: 12:00 AM, July 12, 2020

Dhaka trial recommends Favipiravir in COVID-19 treatment

Bangladesh Society of Medicine (BSM) has found the effectiveness of Favipiravir as the first possible clinically proven drug for the treatment of people infected with COVID-19, says a press release.

After ending trial in Wuhan province of China and Russia, the Dhaka trial revealed similar kind of effectiveness of the Favipiravir in treating the COVID-19 infected patients. 

"To evaluate usefulness and safety of favipiravir in treating the COVID-19 patients, we have conducted a double-blind, placebo-controlled randomised clinical trial for the first time in Bangladesh and we named it as Dhaka Trial," said Principal Investigator of the trial, Dr Ahmedul Kabir, Professor of the Department of Medicine, Dhaka Medical College and Hospital.

Beacon Pharmaceuticals Limited, Bangladesh has manufactured 'Favipira', a preparation of Favipiravir for the treatment of COVID-19 patients.

Stay updated on the go with The Daily Star Android & iOS News App. Click here to download it for your device.

Grameenphone:
Type START <space> BR and send SMS it to 22222

Robi:
Type START <space> BR and send SMS it to 2222


Banglalink:
Type START <space> BR and send SMS it to 2225

Leave your comments

Top News

Top News

Top